20-year assessment of metastatic latency and subsequent time to death after proton therapy for uveal melanomas.

Abstract:

:The aim of this study was to evaluate metastatic latency and survival after the occurrence of metastases in patients with choroidal/ciliary body melanoma treated with proton therapy. This was a retrospective cohort study. All consecutive patients with choroidal/ciliary body melanoma treated with proton therapy between 1991 and 2010 were included. Overall survival, specific survival (SS), local recurrence-free interval, and metastasis-free interval (MFI) were calculated. There were 508 patients. The mean follow-up was 239.4 months. Overall survival and SS rates were 57.2 and 67.6% at 10 years. Pre-equatorial tumor location, advanced tumor stage, and initial exudative retinal detachment were associated independently with SS. Thirty-three percent of the patients (n = 169) had metastases. Local recurrence-free interval and MFI were 91.3 and 65.7% at 10 years, respectively. MFI was shorter in pre-equatorial, large tumors, and/or tumors with exudative retinal detachment. After the occurrence of metastases, the median survival time was 1.25 years and survival probabilities were 62.1% at 1 year, 26.0% at 2 years, and 6.0% at 5 years. Except for age, none of the baseline clinical factors was associated with survival after metastasis occurrence. SS after metastasis occurrence was longer for metastasis occurring more than 10 years after tumor diagnosis (P =0.010). Death after metastasis is independent of initial tumor characteristics. Small tumors still have a risk for metastases after 10 years. Thus, lifelong follow-up is necessary for uveal melanoma patients. Larger series of metastatic patients are needed to evaluate aggressive multimodal treatments of metastases. Death after metastasis is independent of the initial tumor characteristics. Small tumors contraintuitively have a long-life risk of metastases. MFI is associated independently with pre-equatorial location, tumor stage, and retinal detachment.

journal_name

Melanoma Res

journal_title

Melanoma research

authors

Bellocq D,Roy P,Kodjikian L,Mathis T,Nguyen AM,Herault J,Rivoire M,Négrier S,Thariat J,Grange JD

doi

10.1097/CMR.0000000000000519

subject

Has Abstract

pub_date

2020-06-01 00:00:00

pages

272-278

issue

3

eissn

0960-8931

issn

1473-5636

pii

00008390-202006000-00007

journal_volume

30

pub_type

杂志文章
  • The influence of postoperative lymph node radiation therapy on overall survival of patients with stage III melanoma, a National Cancer Database analysis.

    abstract::Recently, TROG 02.01 results showed that in stage III melanoma patients with nodal metastasis, adjuvant radiation to lymph node basin after nodal dissection improves lymph node field relapse without an overall survival (OS) benefit. However, this trial was neither designed nor powered to detect an OS difference. In th...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000292

    authors: Danish HH,Patel KR,Switchenko JM,Gillespie TW,Jhaveri J,Chowdhary M,Abugideiri M,Delman KA,Lawson DH,Khan MK

    更新日期:2016-12-01 00:00:00

  • Single-center real-life experience with low-dose ipilimumab monotherapy in adjuvant setting for patients with stage III melanoma.

    abstract::Ipilimumab is approved for adjuvant melanoma treatment at a dose of 10 mg/kg, but its use is limited owing to high toxicity and treatment-associated costs. We retrospectively analyzed 29 patients who underwent complete resection of stage IIC-III melanoma and were treated with ipilimumab 3 mg/kg in an adjuvant setting....

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000593

    authors: Mangana J,Dimitriou F,Braun R,Ludwig S,Dummer R,Barysch MJ

    更新日期:2019-12-01 00:00:00

  • Sentinel node localization in primary melanoma: learning curve and results.

    abstract::Ninety primary melanoma patients were studied to investigate the importance of adopting the simultaneous use of patent blue dye (PBD) and lymphoscintigraphy plus gamma detection probe to locate the sentinel node (SN). In total 135 SNs in 105 basins were visualized preoperatively under a gamma camera after lymphoscinti...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-199912000-00008

    authors: Testori A,Bartolomei M,Grana C,Mezzetti M,Chinol M,Mazzarol G,Lazzari I,Paganelli G,Geraghty JG,Andreoni B,Veronesi U

    更新日期:1999-12-01 00:00:00

  • Unmet information needs of patients with melanoma in Germany.

    abstract::There is a scarcity of available data on unmet information needs (UINs) of melanoma patients (MPs) from Germany and of MPs with clinical stage IV. In a multicenter cross-sectional survey, we explored the UINs of 529 MPs by applying a standardized questionnaire. Subgroup differences in scope and contents of UINs were d...

    journal_title:Melanoma research

    pub_type: 杂志文章,多中心研究

    doi:10.1097/CMR.0000000000000464

    authors: Brütting J,Bergmann M,Garzarolli M,Rauschenberg R,Weber C,Berking C,Tilgen W,Schadendorf D,Meier F,NVKH supporting group.

    更新日期:2019-04-01 00:00:00

  • Immunosuppression and melanocyte proliferation.

    abstract::Melanocytes are pigmented cells derived from the neural crest; their proliferation is restrained by immune system. The eruption of nevi after an immunosuppressive condition is a peculiar phenomenon indicating that the immune system may play a major role in limiting proliferation of melanocytes. In this review, we anal...

    journal_title:Melanoma research

    pub_type: 杂志文章,评审

    doi:10.1097/CMR.0b013e328322fc20

    authors: Zattra E,Fortina AB,Bordignon M,Piaserico S,Alaibac M

    更新日期:2009-04-01 00:00:00

  • Incomplete Vogt-Koyanagi-Harada disease following treatment with encorafenib and binimetinib for metastatic melanoma.

    abstract::Ophthalmological complications constitute a class effect of treatment with BRAF inhibitors. Encorafenib is a new BRAF inhibitor currently being tested in phase 3 clinical trials for advanced or metastatic melanoma as monotherapy or in combination with the MEK-inhibitor binimetinib. In this study, we present a case of ...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000505

    authors: Diamantopoulos PT,Stoungioti S,Anastasopoulou A,Papaxoinis G,Gogas H

    更新日期:2018-12-01 00:00:00

  • Dacarbazine with or without oblimersen (a Bcl-2 antisense oligonucleotide) in chemotherapy-naive patients with advanced melanoma and low-normal serum lactate dehydrogenase: 'The AGENDA trial'.

    abstract::In a previous large randomized, open-label study, retrospective subset analysis revealed that the addition of the Bcl-2 antisense oligonucleotide oblimersen to dacarbazine (Dac) significantly improved overall survival, progression-free survival, and the response rate in chemotherapy-naive patients with advanced melano...

    journal_title:Melanoma research

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1097/CMR.0000000000000056

    authors: Bedikian AY,Garbe C,Conry R,Lebbe C,Grob JJ,Genasense Melanoma Study Group.

    更新日期:2014-06-01 00:00:00

  • Growth inhibition of subcutaneous mouse melanoma and induction of natural killer cells by liposome-mediated interferon-beta gene therapy.

    abstract::In this study we investigated the antitumour effect and mechanism of action of cationic liposome-mediated murine interferon-beta (IFNbeta) gene therapy in mouse B16F1 melanoma cells in vitro and in vivo. Murine IFNbeta gene transfer by cationic liposome resulted in substantial growth inhibition of B16F1 melanoma cells...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-200308000-00003

    authors: Ryuke Y,Mizuno M,Natsume A,Suzuki O,Nobayashi M,Kageshita T,Matsumoto K,Saida T,Yoshida J

    更新日期:2003-08-01 00:00:00

  • Snail-regulated genes in malignant melanoma.

    abstract::The demonstration that zinc-finger transcriptional repressors can control E-cadherin expression in epithelial cells has provided a new avenue of research in the field of epithelial-mesenchymal transition (EMT). One of these zinc-finger molecules is the transcription factor Snail, which controls gastrulation and neural...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-200508000-00012

    authors: Kuphal S,Palm HG,Poser I,Bosserhoff AK

    更新日期:2005-08-01 00:00:00

  • Sentinel lymph node dissection in stage I/II melanoma patients: surgical management and clinical follow-up study.

    abstract::Selective sentinel lymph node (SLN) dissection is widely used in the management of cutaneous melanoma patients without clinical evidence of nodal metastases. A series of 274 consecutive melanoma patients who underwent melanoma primary excision and SLN mapping at our institutions since 1998, and were thereafter followe...

    journal_title:Melanoma research

    pub_type: 临床试验,杂志文章

    doi:10.1097/00008390-200404000-00016

    authors: Macripò G,Quaglino P,Caliendo V,Ronco AM,Soltani S,Giacone E,Pau S,Fierro MT,Bernengo MG

    更新日期:2004-04-01 00:00:00

  • A purified GM3 ganglioside conjugated vaccine induces specific, adjuvant-dependent and non-transient antitumour activity against B16 mouse melanoma in vitro and in vivo.

    abstract::The presence of substantial amounts of GM3 ganglioside on human melanomas and other tumours, together with its peculiar biological properties, makes this glycolipid a unique target for cancer immunotherapy. B16 mouse melanoma expresses GM3 and constitutes an appropriate model for the development of novel GM3-based vac...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-200106000-00003

    authors: Carr A,Mazorra Z,Alonso DF,Mesa C,Valiente O,Gomez DE,Perez R,Fernandez LE

    更新日期:2001-06-01 00:00:00

  • Phase I-II trial of hyperthermic isolated limb perfusion with cisplatin in the treatment of high risk malignant melanoma of the extremities.

    abstract::Between 1983 and 1990, 59 patients with malignant melanoma were retrospectively reviewed to assess the safety, efficacy and the maximal tolerated dose of cisplatin used in hyperthermic isolated limb perfusion. The median follow-up was 29 months (range 3-54 months). The local recurrence rate was 12% in Stage I, 33% in ...

    journal_title:Melanoma research

    pub_type: 临床试验,杂志文章

    doi:10.1097/00008390-199104000-00007

    authors: Hajarizadeh H,Mueller CR,Woltering EA,Small K,Fletcher WS

    更新日期:1991-04-01 00:00:00

  • Comparison of eumelanin and pheomelanin content between cultured uveal melanoma cells and normal uveal melanocytes.

    abstract::Levels of eumelanin (EM) and pheomelanin (PM) of uveal melanoma cells have not been measured and compared with those of normal uveal melanocytes. EM and PM amounts in four immortal human uveal melanoma cell lines were measured by chemical degradation and microanalytical high-performance liquid chromatography and compa...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0b013e328329ae49

    authors: Hu DN,Wakamatsu K,Ito S,McCormick SA

    更新日期:2009-04-01 00:00:00

  • Use of integrative epigenetic and cytogenetic analyses to identify novel tumor-suppressor genes in malignant melanoma.

    abstract::The objective of this study was to identify novel tumor-suppressor genes in melanoma, using an integrative genomic approach. Data from: (i) earlier reports of DNA loss and gain in malignant melanoma accompanied by comparative genomic hybridization high-definition array data of the entire human genome; (ii) microarray ...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0b013e328344a003

    authors: Mithani SK,Smith IM,Califano JA

    更新日期:2011-08-01 00:00:00

  • Effect of Toremifene in patients with metastatic melanoma: a phase II study of the EORTC Melanoma Cooperative Group.

    abstract::The EORTC Melanoma Cooperative Group conducted a phase II trial (study number 18891) to study the effect of Toremifene in 45 patients with advanced, metastatic melanoma. Male and female patients, median age 61 (range 23-88) years received a mean total dose of 11 g (4.3-62.6) orally for at least 6 weeks. No objective r...

    journal_title:Melanoma research

    pub_type: 临床试验,杂志文章,多中心研究

    doi:

    authors: Kleeberg UR,Engel E,Bröcker EB,Avril F,Israels P,Weiss J,Kangas L,van Glabbeke M,Lentz MA

    更新日期:1993-04-01 00:00:00

  • Life-threatening polymyositis with spontaneous hematoma induced by nivolumab in a patient with previously resected melanoma.

    abstract::Single-agent anti-PD1 antibodies are usually very well tolerated, but serious toxicity can still occur. Despite the PD-1 pathway seems to be relevant in the pathogenesis of immune-related myositis, anti-PD1-related myositis is generally a rare side effect of the treatment and usually not serious. However, its frequenc...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000706

    authors: Liu WK,Naban N,Kaul A,Patel N,Fusi A

    更新日期:2021-02-01 00:00:00

  • Her2/neu is not a commonly expressed therapeutic target in melanoma -- a large cohort tissue microarray study.

    abstract::Melanoma is among the most chemotherapy-resistant malignancies. Numerous new agents have been developed that target specific molecules on cancer cells, including the monoclonal antibody trastuzumab, which targets Her2/neu and has been very beneficial in the treatment of breast cancer. There are conflicting reports in ...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/01.cmr.0000130874.33504.2f

    authors: Kluger HM,DiVito K,Berger AJ,Halaban R,Ariyan S,Camp RL,Rimm DL

    更新日期:2004-06-01 00:00:00

  • Anti-programmed cell death-1 therapy in octogenarian and nonagenarian advanced/metastatic melanoma patients.

    abstract::Immunotherapy with anti-programmed cell death-1 (PD-1) agents is an effective treatment for metastatic melanoma. Octogenarians and nonagenarians represent a significant cohort of melanoma patients. This multicenter retrospective analysis enrolled 499 patients treated with nivolumab or pembrolizumab. Seventy-three pati...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000705

    authors: Cybulska-Stopa B,Ziętek M,Kamińska-Winciorek G,Czarnecka AM,Piejko K,Galus Ł,Ziółkowska B,Kieszko S,Kempa-Kamińska N,Calik J,Zemełka T,Kubiatowski T,Suwiński R,Mackiewicz J,Rutkowski P

    更新日期:2021-02-01 00:00:00

  • Redox regulation of Brn-2/N-Oct-3 POU domain DNA binding activity and proteolytic formation of N-Oct-5 during melanoma cell nuclear extraction.

    abstract::Reversible oxidation sensitivity of N-Oct-3 DNA binding activity was seen when melanoma extracts and recombinant Brn-2 protein were treated with a variety of metals, hydrogen peroxide and the cysteine disulphide bond forming agent diamide. Western blot analysis of diamide-oxidized N-Oct-3 protein indicated that this w...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-199802000-00002

    authors: Smith AG,Brightwell G,Smit SE,Parsons PG,Sturm RA

    更新日期:1998-02-01 00:00:00

  • Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy).

    abstract::Electroporation therapy (EPT) is a novel treatment modality that uses brief, high-intensity, pulsed electrical currents to enhance the uptake of chemotherapeutic agents, vaccines and genes into cells. This technique is potentially useful for patients with secondary and, possibly, some primary tumours. Nineteen patient...

    journal_title:Melanoma research

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1097/00008390-200502000-00008

    authors: Byrne CM,Thompson JF,Johnston H,Hersey P,Quinn MJ,Michael Hughes T,McCarthy WH

    更新日期:2005-02-01 00:00:00

  • Analysis of candidate genes through a proteomics-based approach in primary cell lines from malignant melanomas and their metastases.

    abstract::Proteomics provides a powerful approach for screening alterations in protein expression and post-translational modification associated with particular human diseases. In this study, the analysis of protein expression was focused on malignant melanoma in order to determine the candidate genes involved in tumour progres...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-200508000-00002

    authors: Carta F,Demuro PP,Zanini C,Santona A,Castiglia D,D'Atri S,Ascierto PA,Napolitano M,Cossu A,Tadolini B,Turrini F,Manca A,Sini MC,Palmieri G,Rozzo AC,Italian Melanoma Intergroup.

    更新日期:2005-08-01 00:00:00

  • Clinical significance of serum M30 and M65 levels in melanoma.

    abstract::M30 and M65 are relatively new assays that detect different circulating forms of the epithelial cell structural protein cytokeratin 18. This study was carried out to investigate the serum levels of M30 and M65 in patients with melanoma and the relationship with tumor progression and known prognostic parameters. Fifty-...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0b013e328363e4ab

    authors: Tas F,Karabulut S,Serilmez M,Yildiz I,Sen F,Ciftci R,Duranyildiz D

    更新日期:2013-10-01 00:00:00

  • Metformin: oxidative and proliferative parameters in-vitro and in-vivo models of murine melanoma.

    abstract::Cutaneous melanoma is one of the most lethal cancers because of its increased rate of metastasis and resistance to available therapeutic options. Early studies indicate that metformin has beneficial effects on some types of cancer, including melanoma. To clarify knowledge of the mechanism of action of metformin on thi...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000391

    authors: de Souza Neto FP,Bernardes SS,Marinello PC,Melo GP,Luiz RC,Cecchini R,Cecchini AL

    更新日期:2017-12-01 00:00:00

  • Mutation analysis of candidate genes in melanoma-prone families: evidence of different pathogenetic mechanisms at chromosome 9P21.

    abstract::Putative tumour suppressor genes CDKN2A and CDKN2B (on chromosome 9p21) and CDKN2A-interacting cell growth regulatory genes CDK4 and Id-1 have been demonstrated to be involved in the pathogenesis of malignant melanoma (MM). Mutation analysis of these candidate genes was performed in MM families from southern Italy wit...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-200312000-00006

    authors: Casula M,Ascierto PA,Cossu A,Sini MC,Tore S,Colombino M,Satta MP,Manca A,Rozzo C,Satriano SM,Castello G,Lissia A,Tanda F,Palmieri G

    更新日期:2003-12-01 00:00:00

  • A pilot clinical trial testing topical resiquimod and a xenopeptide as immune adjuvants for a melanoma vaccine targeting MART-1.

    abstract::A vaccine that could expand melanoma-specific T cells might reduce the risk of recurrence of resected melanoma and could provide an alternative or adjunct to standard immunotherapy options. We tested the safety and immunogenicity of a vaccine coupling a melanoma-associated peptide with a xenogenic peptide (to promote ...

    journal_title:Melanoma research

    pub_type: 临床试验,杂志文章

    doi:10.1097/CMR.0000000000000556

    authors: Block MS,Nevala WK,Pang YP,Allred JB,Strand C,Markovic SN

    更新日期:2019-08-01 00:00:00

  • Replacing surrogate measures by direct quantification of ultraviolet radiation exposure in registry-based analyses of seasonality of melanoma diagnoses.

    abstract::Seasonal variation in melanoma diagnoses has been observed in numerous studies that used calendar time indicators. Depending on the latitude (and altitude) of the study region, the magnitude of seasonal and year-to-year variation of ultraviolet radiation (UVR) is neglected in these studies. An alternative approach com...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000205

    authors: Keller AK,Uter W,Pfahlberg AB,Radespiel-Tröger M,Mayer I,Gefeller O

    更新日期:2015-12-01 00:00:00

  • A single-centre experience of patients with metastatic melanoma enrolled in a dabrafenib named patient programme.

    abstract::We studied the efficacy, tolerability and clinical courses of dabrafenib in patients with metastatic melanoma who were ineligible for enrolment into a clinical trial. Between July 2011 and May 2013, patients with unresectable stage III or stage IV, V600-mutated metastatic melanoma who were not eligible for inclusion i...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000036

    authors: Lau DK,Andrews MC,Turner N,Azad AA,Davis ID,Cebon JS

    更新日期:2014-04-01 00:00:00

  • Comparing survival outcomes in early stage desmoplastic melanoma with or without adjuvant radiation.

    abstract::Desmoplastic melanoma (DM) due to its rare and locally aggressive nature, can be difficult to study and to treat effectively. Whether the optimal treatment approach for these tumors should include adjuvant radiation has been unclear in the literature. In this retrospective study of the National Cancer Database, 2390 p...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000532

    authors: Abbott JL,Qureshi MM,Truong MT,Sahni D

    更新日期:2019-08-01 00:00:00

  • Molecular and immunohistochemical analyses of uveal melanoma patient cohort.

    abstract::Uveal melanoma is a rare form of melanoma and the most frequent primary eye malignancy in adults. The major molecular alterations underlying uveal melanoma pathogenesis affect mainly the GNAQ, GNA11, SF3B1, and BAP1 genes. In this study, we somatically genotyped 31 Brazilian uveal melanomas for BRAF, GNA11, GNAQ, SF3B...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000523

    authors: Sarubi HC,Pereira NB,Gomes CC,Gomez RS,Carmo ACM,Melo FM,Bastos-Rodrigues L,Pedrosa MS,Friedman E,De Marco L

    更新日期:2019-06-01 00:00:00

  • Immune-related Bell's palsy in melanoma patients treated with immune checkpoint inhibitors.

    abstract::Immune-checkpoint inhibitors (ICIs) exposed the oncology community to novel immune-related adverse events (irAEs). Here, we report on a retrospective analysis of patients with melanoma who developed an ICI-related, unilateral, acute and peripheral facial nerve paralysis (Bell's palsy).We retrospectively reviewed all t...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000715

    authors: Beninato T,Fucà G,Di Guardo L,Vetrano I,Valeri B,Nesa F,Del Vecchio M,Cimminiello C

    更新日期:2021-01-22 00:00:00